Log in to search using one of your social media accounts:

 

AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis C, including those with compensated cirrhosis[1] VIEKIRAX consists of a 12-week, two direct-acting antiviral, fixed... Biopharmaceuticals, RegulatoryAbbVie, VIEKIRAX, ombitasvir, paritaprevir, ritonavir
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Bellan M, Sainaghi PP, Minh MT, Minisini R, Molinari L, Baldrighi M, Salmi L, Barbaglia MN, Castello LM, Ravanini P, Avanzi GC, Pirisi M Abstract AIM: Plasma Gas6 was tested as an alternative to Baveno VI criteria (liver stiffness 150 × 109/l) in an endoscopy-sparing strategy. METHODS:  A total of 160 patients with chronic hepatitis C and advanced fibrosis/cirrhosis underwent, on the same occasion, liver elastography, upper endoscopy, a platelet count and serum Gas6 measurement Results: A total of 74/160 (46%) patients had esophageal varices, that were small (diameter 
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Conclusions Liver cirrhosis, high APRI levels, and IL28B rs12979860 at baseline are independent risk factors for HCC development in patients without SVR after peg-IFN combination therapy.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
CONCLUSIONS: In recent years, improvements in surgical techniques and immunosuppressive therapies have helped prolong survival of patients who undergo liver transplant. However, this also has led to a rise in the incidence of long-term complications such as de novo malignancy. These patients are more likely to develop de novo malignancy than the general population, for which chronic immunosuppression is identified as a major risk factor. Early diagnosis and treatment of de novo malignancies can help obtain better prognosis and higher survival rates in these patients. PMID: 29237362 [PubMed - as supplied by publisher]
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - Category: Transplant Surgery Authors: Tags: Exp Clin Transplant Source Type: research
This article is protected by copyright. All rights reserved.
Source: Journal of Viral Hepatitis - Category: Infectious Diseases Authors: Tags: Original Paper Source Type: research
Authors: Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W Abstract There have been few studies on relapse after a sustained virological response in hepatitis C virus (HCV) patients treated with interferon-free regimens. Thus, the risk of late relapse in patients treated with interferon-free therapy remains unclear. A 67-year-old woman with HCV genotype 1b and liver cirrhosis received oral daclatasvir and asunaprevir. Combination therapy was stopped after 4 weeks because of an episode of encephalopathy. Nonetheless, an HCV polym...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Hepatitis C virus (HCV) infection is a major cause of viral hepatitis with a global seroprevalence estimated to be greater than 185 million [1]. Approximately 75% to 85% of patients with HCV infection develop a chronic hepatitis C (CHC) infection [2]. In addition to the direct negative impact by the virus on the liver, where more than 40% of CHC infections leads to liver cirrhosis after 30 years [3], CHC infection is also associated with extrahepatic manifestations including kidney disease, most commonly membranoproliferative glomerulonephritis with or without cryoglobulinemia [4].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Opinion statementWith the recent introduction of direct acting antiviral agents for hepatitis C treatment, many patients are receiving these highly effective therapies. Patients with advanced fibrosis or cirrhosis prior to antiviral treatment will have decreased but persistent risk of hepatocellular carcinoma following cure of hepatitis C. This review will discuss this risk and review current surveillance recommendations.
Source: Current Treatment Options in Infectious Diseases - Category: Infectious Diseases Source Type: research
ObjectivesStudies evaluating the efficacy and safety of the fixed‐dose combination ledipasvir (LDV)/sofosbuvir (SOF) in patients coinfected with HIV‐1 and hepatitis C virus (HCV) have mainly included treatment‐naïve patients without cirrhosis. We aimed to evaluate the efficacy and safety of this combination in treatment‐experienced patients with and without cirrhosis. MethodsWe conducted a multicentre, open‐label, double‐arm, nonrandomized study in patients coinfected with HIV‐1 and HCV genotype 1 with and without cirrhosis, who had good viral suppression on their antiretroviral regimens. All patients we...
Source: HIV Medicine - Category: Infectious Diseases Authors: Tags: Original Research Source Type: research
Non-alcoholic fatty liver disease (NAFLD) comprising non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), together with their complications of cirrhosis, liver failure and liver cancer will be the predominant liver disease for the conceivable future. Traditionally, viral hepatitis has been the focus of basic and clinical research, and the bread and butter for clinicians in the field. However, with the advent of therapies that suppress hepatitis B virus replication and the shift in standard of care for the treatment of hepatitis C to highly effective direct acting antivirals, the focus of clinical prac...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research
Publication date: Available online 6 December 2017 Source:Revista Clínica Española (English Edition) Author(s): M.J. Vivancos, A. Moreno, C. Quereda Hepatitis C virus infection is a significant public health problem. The introduction of direct-acting antiviral agents, whose efficacy is greater than 90% in all patient groups (including those with cirrhosis), has represented a highly relevant change compared with classical interferon-based therapies. Tolerance for these antiviral agents is significantly better, and the treatment duration is shorter. This review updates the treatment of hepatitis C virus infect...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
More News: Cirrhosis | Hepatitis | Hepatitis C | Norvir | Pharmaceuticals